Global Obesity-Diabetes Drugs Market Poised for Significant Growth, Reaching USD 97,567.4 Million by 2034

As per Future Market Insights’ latest industry analysis, the global obesity-diabetes drugs market was valued at around USD 54,452.0 million in 2023 and is anticipated to exhibit moderate market growth with CAGR of 5.8% over the forecast period. The sales of such drugs are likely to attain a valuation of USD 97,567.4 million by 2034.

Therapeutic drugs have a remarkable role in the effective management of obesity-diabetes. It aids obesity-diabetic patients in controlling blood sugar levels and preventing further complications in diseased patients. The prevailing cases of obesity-diabetes due to the growing number of population following sedentary lifestyle with their limited focus towards performing any physical activity majorly contributes to the growth of the segment. The inherited genetic complexities faced by the varied population of the emerging countries further anticipates the market growth.

Get Sample Report Visit: https://www.futuremarketinsights.com/reports/sample/rep-gb-19677

The improved focus of pharmaceutical manufacturers towards investment in development of new drugs for the treatment of the obesity related diabetes to support the demand of the drugs. Strategic initiatives in collaboration with hospitals and government agencies for raising awareness of the disease augments will also aid the growth of the market in the near future. The growing focus of government authorities of developing regions on improving healthcare infrastructure in their countries for improving healthcare facilities and services is further anticipating the market growth.

Key Takeaways from the Market Study:

• By therapy, the drug therapy to hold the dominant share of 9% in 2024 in the market. The growth of the segment is majorly due to its easy availability and affordability among common population.
• By route of administration, oral route of administration segment to account for a major share of 6% in the market in 2024. This is due to its convenience in consumption. In addition, its safety and efficacy profile furthers augments its market growth.
• By distribution channels, institutional segment which includes hospitals will dominate the market by holding the market share of 7% in 2024. The increasing footfall of patients to the hospitals for their regular check-up anticipates the growth of the segment.
• North America region is considered the leading region with a value share of 5% in 2024. The rising prevalence of obese population in the region surges the growth of the market in the region.

“Novel pharmacological discoveries targeting particular pathways in metabolic diseases, along with personalized medicine methods, are specifically driving growth in the obesity diabetes drug industry,” says an analyst of Future Market Insights.

Customization Available Upon Request: https://www.futuremarketinsights.com/customization-available/rep-gb-19677

Market Competition:

The primary approach taken by the key operating players in the industry is to develop novel therapeutic options for the management of obesity-diabetes. The major aim of the key players is to expand their product portfolio through the introduction of new products and uphold their position in the market. Following are a few examples of research and development activities made by them to be at the top position:

• In November 2023, Eli Lilly and Company received approval for Zepbound from the U.S. FDA. This Zepbound injection is indicated for the treatment of adults with obesity and have weight related metabolic problems including type 2 diabetes mellitus.
• In November 2023, Astrazeneca collaborated with Eccogene, a Chinese biopharmaceutical company for research and development of ECC5004, which is an investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) indicated for the treatment of obesity, and type 2 diabetes.

Leading Obesity-Diabetes Drugs Brands:

• Boehringer Ingelheim International GmbH.
• Eli Lilly and Company
• Sanofi
• Vertex Pharmaceuticals Incorporated
• Novo Nordisk A/S
• AstraZeneca
• MannKind Corporation
• Xeris Pharmaceuticals
• Amphastar Pharmaceuticals, Inc.
• Novartis
• Bayer AG
• GLENMARK PHARMACEUTICALS LTD.
• Others

A Detailed Full Report: https://www.futuremarketinsights.com/checkout/19677

Key Segments of Market Report:

By Therapy:

As per product type, the industry has been categorized into drug therapy (Meglitinides, sulfonylureas, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, bile acid sequestrants and GLP-1 receptor agonists), and insulin therapy (rapid acting insulin, short acting insulin, intermediate acting insulin, long acting insulin and biphasic insulin.

By Route of Administration:

This segment is further categorized into oral administration, nasal administration and parenteral administration (subcutaneous, intramuscular and intravenous).

By Distribution Channel:

Different sales channels include Institutional sales (hospitals, specialty clinics, and others), retail sales (retail pharmacies, and drug stores) and online pharmacy.

By Region:

Industry analysis has been carried out in key countries of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube